"Latigo Secures $135M for Non-Opioid Pain Medicine, Chasing Vertex Success"
TL;DR Summary
Latigo Biotherapeutics, a non-opioid drug developer, has emerged with a $135 million Series A funding after years of development, targeting the same Nav1.8 as Vertex Pharmaceuticals. The company aims to address pain management without the risk of addiction by focusing on the peripheral nervous system.
Topics:business#biotech-investment#biotechnology#latigo-biotherapeutics#non-opioid-drug#pain-management#vertex-pharmaceuticals
- Latigo, a pain biotech years in the making, emerges with $135M on heels of Vertex PhIII success Endpoints News
- Biotech launches with $135 million for Vertex-competing pain medicine STAT
- Latigo, running behind Vertex in non-opioid pain race, raises $135M to catch up FierceBiotech
- Latigo Launches into Non-Opioid Pain Medicine Space with $135 Million Series A BioSpace
- Latigo Biotherapeutics raises $135 mln for non-opioid painkillers ETHealthWorld
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
62%
119 → 45 words
Want the full story? Read the original article
Read on Endpoints News